Gerresheimer Partners with RxCap to Enhance Patient Adherence Solutions in U.S. Pharmacies

Gerresheimer, a prominent provider of systems and solutions for the pharma, biotech, and cosmetics industries, has announced a partnership with RxCap, a U.S. digital health company. This collaboration gives Gerresheimer’s subsidiary, Centor, exclusive U.S. distribution rights for RxCap’s adherence solutions, aiming to improve patient health outcomes through enhanced medication adherence monitoring.

Through this strategic alliance, Centor will integrate RxCap’s connected prescription vial closures and cloud-based software into its offerings, providing pharmacies the capability to monitor patient adherence without additional patient effort. RxCap's technology, which reports medication usage through cellular signals to cloud software, enables pharmacy staff to promptly verify patient compliance and facilitates direct patient communication to ensure medication uptake as prescribed.

The partnership not only positions Centor to lead in the remote therapeutic monitoring market but also aligns with Gerresheimer’s focus on expanding its digital healthcare solutions. Gerresheimer also gains a minority stake in RxCap and a seat on their Board of Directors, underscoring a deep commitment to advancing digital health innovations that contribute to improved treatment outcomes and prevention of costly medical interventions.